Apr. 1 at 3:33 PM
$FBIOP $FBIO I was burned by this company when they had their reverse split a few years back. There was a major bungle with IV Tramadol (ATXI) and the FDA's concerns with opioid stacking turned out to be entirely legitimate. I swore I wouldn't return.
Now, like a dog returns to its vomit, I am here again. This time, with a sober-minded understanding of how this company gets to cashflow positivity.
Back then, IV Tramadol was their bridge to cashflow positivity. Now, they have royalty streams from UNLOXCYT and ZYCUBO to nudge them to green EBITDA.
There is an order of things, and the idea that this will "moon" to HC Wainwright's 17 target without them first making good to their creditors is a pipe dream.
By all means, establish a long position in FBIO at your discretion. But when you do, understand that by doing so, you enthusiastically take on the responsibility of paying the holders of FBIOP their
$0.1953 per month per share for every month it has been suspended since July of 2024.
